Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
79 HKD | -0.88% | +6.40% | +39.70% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 168.3 and 73.84 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+39.70% | 1.72B | D- | ||
-9.62% | 24.29B | B | ||
-6.85% | 16.91B | A | ||
+8.85% | 13.91B | B | ||
-13.54% | 2.1B | - | ||
+8.20% | 1.82B | B+ | ||
+12.09% | 579M | - | ||
0.00% | 427M | - | - | |
+24.28% | 133M | - | ||
+25.30% | 98.18M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 6699 Stock
- Ratings Angelalign Technology Inc.